Introduction
Peripheral blood mononuclear cells (PBMC), consist of subpopulations of cells that are involved in specialized effector and regulatory functions in response to immunological stimuli. As a general rule, T lymphocytes are responsible for cellular immune response and humoral response is mediated by B lymphocytes. Due to their immunological specificity, genetically modified effector cells have been used for developing cell-based therapies. 1 Genetically modified lymphoid cells have been used to deliver therapeutic proteins in experimental rheumatoid arthritis, 2 adenosine deaminase deficiency, 3 and graftversus-host disease. 4, 5 Genetically modified immune cells have also been shown to increase antitumor reactivity. 6 In addition to their potential for developing cell-based therapies, transiently transfected lymphoid cells are of value to understand the role of certain genes that may be differentially expressed in different lymphoid subpopulations in response to a stimulus. 7, 8 For this purpose, PBMC provide an easily accessible cell population, which more closely represents a physiological system than established cell lines. Unfortunately, PBMC have proven to be very difficult to transfect, using both viral as well as nonviral gene delivery systems.
Among viral vectors, retroviral vectors are commonly used for gene delivery to lymphoid cells because of their ability to transduce hematopoietic cells, although they generally offer low transduction efficiency. In some cases, Pseudotyped retroviruses have also been used in order to increase the efficiency to transduce lymphoid cells. [10] [11] [12] [13] In these studies envelope protein of Moloney murine leukemia virus has been replaced by the G glycoprotein of vesicular stomatitis virus to achieve vast host range, 10, 11 or with the glycoproteins of HIV for targeting specific, CD4-positive T cells. 12, 13 In comparison to retroviruses, adenoviral vectors are used less frequently for transducing lymphoid cells, 14, 15 partly because lymphoid cells inadequately express the CAR (receptor for adenovirus and coxsackie virus) receptors that are essential for the attachment and entry of adenoviruses into cells. 15 Besides retro-and adenoviral vectors, adeno-associated, 16 and SV40-based 17 viral vectors have been used in limited studies to transduce lymphoid cells. Although the viral vectors continue to evolve to offer a better system, the major disadvantages are due to limitation of the length of DNA to be inserted, difficulties in consistent production of vectors and immunogenicity of viral proteins.
Nonviral gene delivery systems, on the other hand, appear to allow more flexibility with respect to the DNA sequences to be inserted into cells but provide much lower efficiency of transfection. The attempts to facilitate transfer of DNA into primary T or B lymphocytes using nonviral vectors have met with limited success. 18, 19 Several rate-limiting steps, such as suboptimal attachment and internalization through the cell membrane, and/or inadequate release of vector-DNA complexes from the endosomes and transport of DNA to the nucleus, may be partially responsible for the inefficiency of nonviral vectors for gene delivery to lymphoid cells. To overcome some of these hurdles, nonviral vectors have been modified by covalent attachment of various ligands, which facilitate entry of DNA into cells via specific receptors. [20] [21] [22] [23] This approach was explored by Buschle et al 24 to transfect primary lymphocytes using an anti-CD3 antibody conjugated to poly-l-lysine to facilitate gene transfer via the CD3 receptor. Using anti-CD3-poly-l-lysine for gene transfer, they observed very efficient gene delivery to T lymphoblastoid cell lines, however, the efficiency of gene expression in prestimulated PBMC was low.
Recently, Kircheis et al 25 used a cationic polymer, polyethylenimine (PEI), to investigate combined effect of specificity of receptor-mediated gene delivery and hightransfection potential of PEI. PEI has been shown to be an efficient nonviral vector for gene delivery to a variety of cell types, both in vitro, as well as in vivo. [26] [27] [28] [29] [30] [31] [32] The distinctive properties of PEI, such as DNA-binding and condensation, along with its high buffering capacity is considered to protect DNA from degradation. 29 PEI acts as a 'proton sponge' in the acidic environment of the lysosomes, and promote release of DNA from the lysosomes. 33 Furthermore, PEI is also shown to promote transgene localization to the nucleus in mammalian cells. 34, 35 When these properties of PEI were combined with the specific mechanism of receptor-mediated gene delivery, ligand-conjugated PEI resulted in higher transfection efficiency in various tumor cell lines. 25 In the studies reported here, we have used PEI coupled to various ligands specific for the receptors present on PBMC to assess gene delivery to human PBMC. It was observed that PBMC were efficiently transfected by anti-CD3-PEI, whereas anti-ICAM1-PEI and anti-MHC class I-PEI did not transfer DNA effectively. The results suggest that in addition to ligand-receptor interaction and endocytosis of the DNA/vector complexes, efficiency of expression of a transgene is affected by signaling events following receptor engagement.
Results
Transfection of human PBMC with pGL3 plasmid DNA Expression of the luciferase gene in human PBMC was assessed following transfection of PBMC with pGL3 vector using various nonviral gene delivery carriers. The attempts to transfect PBMC using Superfect, Lipofectamine or DEAE-dextran were unsuccessful (data not shown). However, consistent gene expression was achieved when PBMC were transfected either by electroporation or receptor-mediated gene delivery using anti-CD3-PEI conjugates. The results from a representative experiment comparing relative efficiencies of electroporation and anti-CD3-PEI-mediated gene delivery are summarized in Figure 1 . A moderate level of gene expression was observed when cells were transfected by electroporation. The transgene expression was augmented when transfected cells were stimulated with a transcriptional activator, PMA (20 ng/ml). In contrast, significantly higher luciferase activity was seen in the cells transfected using anti-CD3-PEI in the absence of stimulation with PMA. Since CD3-receptor crosslinking by anti-CD3 antibody induces the T cell activation signaling cascade, we wanted to determine if cells transfected using anti-CD3-PEI were capable of responding to another activation signal, eg PMA. As shown in Figure 1 , luciferase activity was further augmented approximately 60% when transfected cells were treated with PMA (from RLU 45 406 ± 851 to 72 361 ± 378).
Similar to various nonviral gene delivery vectors, nontargeted PEI was not effective in transfecting PBMC (data not shown). Based on the specificity of anti-CD3-PEI to target CD3-positive cells in the studies by Kirches et al, 25 it is highly likely that the cell population expressing the luciferase may be T lymphocytes. However, since PBMC were not fractionated to enrich T lymphocytes, the transfected cell population has been referred to as PBMC. The efficiency of transfection, in terms of the transgene expression, was variable in different PBMC samples. The average luciferase expression without PMA stimulation of PBMC from nine different donors was 14 848 RLU/1 × 10 5 cells/s (range 1236-45 406 RLU/1 × 10 5 cells/s). Stimulation of the transfected cells with PMA did not affect the variability in gene expression. Despite the variability, luciferase activity was consistently seen in all PBMC samples transfected using anti-CD3-PEI.
Effect of prestimulation of PBMC on the efficiency of transfections using anti-CD3-PEI In order to determine optimal conditions for gene delivery to PBMC using anti-CD3-PEI, experiments were performed using unstimulated PBMC and PBMC stimulated with PHA. As shown in Figure 2a , naive, unstimulated PBMC did not express the transgene, whereas, transgene expression was achieved by prestimulation of PBMC with PHA. Optimal transfection efficiency was achieved when transfections were carried out 48-72 h after PHA stimulation. Addition of exogenous IL-2 to PHA blasts before transfection resulted in increased gene expression, optimally, when added 24 h before transfection ( Figure  2b ). Interestingly, addition of IL-2 to the cells 72 h before gene delivery (IL-2 added along with PHA on day 0) resulted in gene expression even lower than the cells that did not receive IL-2 before transfection. These data suggest that the efficiency of gene expression is influenced by different culture conditions, including presence of either endogenously produced (following stimulation with PHA) or exogenously supplemented growth factors such as IL-2.
Kinetics of transgene expression following anti-CD3-PEImediated gene delivery Optimally prestimulated PBMC were transfected separately with pGL3 or pEGFP vectors to assess duration of gene expression. The percentage of cells expressing GFP was determined by flow cytometry using standard procedures and analysis with a FACScan cytometer (Becton Dickinson, Mountain View, CA, USA) ( Figure 3a and Table 1 ). The transfected cells were monitored for luciferase activity after 24, 48, 72 and 96 h following transfection (Figure 3b) . Expression of both luciferase and GFP was detected up to 96 h after transfection, although gene expression began to gradually decrease after 48 h. Although the percentage of GFP positive cells is likely to be variable in different PBMC samples, as high as 56-43% of cells expressing GFP were detected up to 72 h with significant fluorescence intensity. The decrease in the percentage and the intensity of GFP-positive cells by 96 h Optimally prestimulated PBMC were transfected with pEGFP. The GFP expression was quantitated daily for 4 consecutive days using FACS analyzer (Becton Dickinson). The data from histograms shown in Figure 3a are summarized in Table 1 .
could be due to overproliferation of GFP nonexpressing cells or GFP-expressing cells that did not transfer the transgene into the daughter cells after cell division.
Gene transfer to PBMC using ICAM1 and MHC class I surface receptors Since efficient gene delivery could be obtained using receptor-mediated endocytosis via the CD3 surface receptor, we sought to address if gene delivery could be achieved via other receptors expressed on PHA-activated PBMC. We used PEI conjugated to anti-ICAM1 or anti-HLA class I (W6/32) monoclonal antibodies, to target ICAM1 or HLA class I receptors on the cell surface, respectively. Neither of these antibodies coupled PEI conjugates were as efficient as anti-CD3-PEI (data not shown). Since only anti-CD3-PEI was effective in transfecting PBMC, we asked if receptor-ligand interaction and internalization are sufficient for gene expression, and is activation following engagement of the CD3 receptor with anti-CD3 antibody important for gene expression.
To address this, PBMC transfected with anti-ICAM1-PEI or anti-HLA class I-PEI were cultured in the presence of immobilized anti-CD3 antibody. Expression of the transgene was significantly augmented when the cells transfected using anti-ICAM1-PEI were cultured in the presence of immobilized anti-CD3 antibody (Figure 4 ). The transgene expression was as good as or better than that obtained in transfection of the same PBMC using anti-CD3-PEI. The gene expression in anti-CD3-PEI transfected cells was further augmented when these cells were cultured in the presence of anti-CD3-PEI. In comparison, anti-HLA class I-PEI and nontargeted PEI-transfected PBMC did not show appreciable increase in luciferase expression in the presence of immobilized anti-CD3 antibody. The gene expression in these transfections, even in the presence of immobilized anti-CD3 antibody, was 3.5-12 times less than that achieved using anti-CD3-PEI in the absence of immobilized anti-CD3.
Discussion
In the present studies, we have shown that efficient gene delivery to PHA-activated human PBMC was achieved via the CD3 receptor using anti-CD3-PEI as a gene delivery vector, whereas gene delivery using anti-ICAM1-PEI and anti-HLA class I-PEI was not efficient. Receptormediated gene delivery has been shown to be effective for a variety of cell types, including lymphoid cells. [20] [21] [22] [23] Increased transfection efficiency for lymphoblastoid cell lines has been achieved by targeting the CD3, CD4 or the transferrin receptors using anti-CD3-poly-l-lysine, 24 anti-CD3-PEI, 25 transferin-polycation, 36 transferin-PEI 25 or anti-CD4-poly-l-lysine. 37 Among these vectors, anti-CD3-poly-l-lysine was used for gene transfer to previously activated PBMC, which resulted in transgene expression in about 5% cells. 24 In light of relatively low efficiency of transfection of PBMC shown in these studies, we have achieved a significant improvement in transfection of PBMC using anti-CD3-PEI. The increase in transfection efficiency using anti-CD3-PEI in comparison with anti-CD3-poly-l-lysine could be primarily attributed to distinctive properties of PEI, such as its buffering capacity for the condensed DNA in the acidic environment of endosomes and promoting release of DNA from the endosomes. 26 In these studies by Kircheis et al, 25 30-1000-fold enhancement in transgene expression was observed in three out of five tumor cell lines when these cells were transfected with PEI conjugated to the ligands against specific surface receptors on various tumor cell lines. In the present studies, in addition to showing efficacy of anti-CD3-PEI as a gene delivery vector to human PBMC, we have shown that previously frozen lymphocytes can also be transfected using anti-CD3-PEI and assessed transgene (GFP) expression in individual cells by FACS analysis.
In the present studies, we observed disparity in transfection efficiency of PBMC using anti-CD3-PEI, anti-ICAM1-PEI and anti-HLA class I-PEI. These observations suggest that for efficient transfection of primary cells, like PBMC, receptor binding and internalization may be receptor-specific. These results also suggest that higher efficiency of anti-CD3-PEI-mediated transfection of PBMC, as compared with anti-ICAM1-PEI or anti-MHC class I-PEI, could be partly attributed to activation of transfected cells following CD3/anti-CD3 interaction. This is supported by the observations that efficiency of anti-ICAM-1-PEI-, as well as anti-CD3-PEI-mediated transfection of PBMC was augmented in the presence of immobilized anti-CD3 (Figure 4) . It remains to be determined if activation of transfected cells following CD3/anti-CD3 interaction promotes internalization of the bound ligand/PEI/DNA complex or augments expression of a transgene in the internalized complex, or it is a combined effect of both. Increased membrane fluidity due to CD3/anti-CD3 crosslinking could promote better internalization of a DNA/vector complex bound to another receptor. Moreover, transcriptional activation following anti-CD3 crosslinking could potentially enhance responsiveness of the internalized reporter gene. We observed marginal increase in the transfection efficiency using nontargeted PEI in the presence of immobilized anti-CD3 antibody. A similar effect of immobilized anti-CD3 antibody along with anti-CD28 antibody has been reported when primary T lymphocytes were transduced with retroviral vectors. 9 Therefore, it is possible that costimulation with immobilized anti-CD3 antibody can enhance gene delivery by any vector and may not be restricted to receptor-mediated gene delivery. However, the differences in the efficiency to transfect PBMC by anti-ICAM1-PEI, anti-HLA class I-PEI and nontargeted PEI in the presence of immobilized anti-CD3 antibody, suggest that the unique properties of different receptor-ligand interactions can also affect the efficiency of a transgene expression.
Thus anti-CD3-PEI conjugates appear to offer multiple advantages derived from both PEI, as well as anti-CD3 antibody for efficient gene delivery to primary CD3-positive lymphoid cells. However, there are other consequences of the CD3/anti-CD3 antibody interaction, which need to be considered. For example, activationinduced expression of a transgene in PBMC could potentially be affected if PBMC were already activated during gene transfer using anti-CD3-PEI. The results shown in Figure 1 indicate that expression of a transfected gene whose expression is driven by a constitutive promoter can be further augmented by another stimulus, such as PMA, even though PBMC were apparently activated by PEI-conjugated anti-CD3 antibody. In addition to these studies, we have successfully used anti-CD3-PEI to transfect PBMC, with or without additional activation and have assessed functional activity of a transgene consisting of an activation inducible promoter (unpublished observations). Thus activation via the CD3 receptor during transfection does not seem to affect subsequent activation by a different stimulus.
Another outcome of the CD3/anti-CD3 interaction during anti-CD3-PEI-mediated gene delivery could lead to apoptosis of transfected cells. We have often observed some apoptotic cells in transfected cultures within 24 h, which could partly be due to activation induced cell death (AICD) as a result of Fas/Fas ligand (FasL) interaction in anti-CD3-PEI transfected PBMC. In addition to Fas/FasL-mediated AICD, TNF␣ produced by anti-CD3 activated T cells may also be responsible for the observed apoptosis. Of importance is the observation that in cytokine-induced killer cells (CIK), nonviral gene delivery vectors, which were not coupled to anti-CD3 antibody, induced apoptosis of the transfected cells by production of TNF␣. 38, 39 In the present investigations, we have assessed production of TNF␣ in a set of transfections. Anti-CD3-PEI-transfected cells produced 50.83 pg/ml of TNF␣ in comparison with no production of TNF␣ (below detectable level) by nontransfected cells. Thus, both TNF␣ and FasL could be responsible for some apoptotic events immediately following anti-CD3-PEI-mediated transfection of PBMC. However, beyond 24 h after transfection, fewer apoptotic cells were seen in the transfected cultures. The overall gene expression in PBMC using anti-CD3-PEI, thus appears to be a balance between the beneficial effects for promoting gene expression and unfavorable effects, such as induction of apoptosis, that occur due to triggering the CD3 receptor by anti-CD3 antibody conjugated to PEI.
Thus considering the risks and benefits associated with anti-CD3-PEI-mediated gene delivery, it appears that development of such gene delivery protocols using nonviral vectors, where high percentage of primary cells can be transfected in a specific manner, is of value. This method of transfecting human primary lymphocytes can be used as another tool for analyzing gene expression and dissecting signaling pathways with an ability to introduce exogenous genes. This approach can be used for assessing effects of various pharmacological agents or physiological stimuli on expression of certain genes or the promoters of activation-inducible genes, following their introduction in a primary lymphoid cell population. Most of the experiments reported in these studies were performed using cryopreserved PBMC samples. Thus an added advantage of using anti-CD3-PEI for gene delivery is the ability to use either freshly isolated or cryopreserved lymphocytes, that can be efficiently transfected within 48-72 h of thawing. Finally, as shown by genetic modification of T cells using viral vectors, 1-5 a desired lymphocyte subpopulation can be genetically engineered using targeted nonviral gene delivery methods to carry therapeutic proteins to the target sites in a specific manner.
Materials and methods
Isolation and culturing of mononuclear cells from human peripheral blood lymphocytes Heparinized venous blood was obtained from healthy volunteers. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque (density = 1.077 g/ml, Amersham Pharmacia Biotech, Piscataway, NJ, USA) density gradient centrifugation at 400 g for 20 min at room temperature. The cells at the interface were washed 2× with Dulbecco's phosphate buffered saline (DPBS) (Gibco BRL), and resuspended at 1 × 10 6 cells/ml in complete medium (RPMI-1640 + 10% FBS, 25 mm Hepes, 50 g/ml gentamycin, 1× non-essential amino acids, 1× sodium pyruvate, 5 × 10 −5 m 2 ME, and 1× glutamine (Life Technologies Gibco/BRL, Rockville, MD, USA)). PBMC were stimulated with phytohemaglutinin (PHA-P) at 1 g/ml (Sigma, St Louis, MO, USA) and were split 1:2 as and when needed. In some cultures, 10 units/ml of human recombinant interleukin-2 (rIL-2) (Sigma) was added 24 h before transfection. PHA-stimulated PBMC are referred to as PHA blasts.
Transfection of PBMC by electroporation PHA blasts were resuspended at 2 × 10 6 cells in 20 l complete medium containing 10 units of human rIL-2. The cells were incubated with 5 g of pGL3-control plas-mid DNA for 20 min at room temperature. The cell/DNA mixture was placed between the electrodes of a microchamber (Life Technologies) and electroporated on ice at 60 F, low ohms and 135 volts (900 volts/cm) using BRL CellPorator. The cells were incubated for an additional 15 min at room temperature, suspended in 2.5 ml of complete medium and cultured at 37°C in a sixwell plate (Corning Costar, Acton, MA, USA). The cells were harvested for assessment of the transgene expression at 24, 48 or 72 h after transfection.
Transfection of PBMC using anti-CD3-PEI PHA blasts used for transfection were either supplemented with 10 units/ml of human rIL-2 before transfection or were left without exogenous supplementation of human rIL-2. DNA/anti-CD3-PEI complexes were prepared as described earlier. 25 Briefly, 10 g DNA (pGL3-control DNA or pEGFP DNA) was diluted in 250 l Hepes buffered saline (HBS, 150 mm NaCl, 20 mm Hepes pH 7.3). Six g anti-CD3-PEI (refers to the concentration of PEI in the conjugates) diluted in 250 l HBS was added to previously diluted DNA and mixed vigorously. The DNA/anti-CD3-PEI complexes were allowed to form at room temperature for 25-30 min. The complexes were then gently mixed with the cells (5 × 10 5 cells in 1.5 ml complete medium in a 24-well plate). After a 4 h incubation at 37°C, the medium containing the DNA/anti-CD3-PEI mixture was replaced with 2.0 ml of complete medium containing human rIL-2 (10 units/ml). The cells were transferred to a humidified incubator at 37°C containing 5% CO 2 for 24, 48, 72 or 96 h before assessment of the transgene expression.
Luciferase assay
Luciferase activity was analyzed using the luciferase assay system (Promega, Madison, WI, USA). Briefly, the cells were pelleted at 14 000 r.p.m. in a microcentrifuge for 5 min. The cells were lysed for 10 min in 100 l of 1× lysis buffer and centrifuged for 5 min at 14 000 r.p.m. to remove nuclei. Luciferase activity in the supernatant was quantitated using duplicate 20 l samples on a Wallac Microbeta luminometer (model 1450-024), in which the substrate (Luciferase assay system kit, Promega) is injected into each well before counting.
Reagents pGL3-control plasmid DNA (referred to as pGL3) was purchased from Promega and pEGFP plasmid DNA was purchased from Clontech, Palo Alto, CA, USA. Plasmids were prepared in the laboratory using standard molecular biology techniques. Transfecting reagents anti-CD3-PEI, anti-HLA class I (W6/32)-PEI and anti-ICAM1-PEI were supplied by Dr Ernst Wagner (Boehringer Ingelheim, Vienna, Austria). Anti-CD3-PEI conjugates were prepared using Ortho-mune-OKT3 antibody (Ortho Diagnostic Systems, Raritan, NJ, USA). 25 Anti-HLA class I (W6/32) antibody (hybridoma was purchased from ATCC) and anti-ICAM1 (BIRR1) 40 were generated and purified at Boehringer Ingelheim, R&D, Ridgefield, CT, USA. Transfections using Superfect (Qiagen, Valencia, CA, USA), Lipofectamine (LifeTechnologies Gibco/BRL) and DEAE-Dextran (Promega) were performed according to the suppliers' protocols. Phytohemagglutinin-P (PHA-P), human rIL-2 and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma.
